INDEX TO VOLUME 89

Editorials, Letters to the Editor, Case Reports, Short Reports and Supplements are indicated by (E), (L), (CR), (SR) and (S) after the page numbers respectively.

Abba AA 701-703(CR) Abdulmumini T 199-207 Abe S 509-511(CR) Acetylcysteine effects on hyperoxic lung in rat 311(L) Aerosol particle disposition between two lungs 15-19 Afzal M 701-703(CR) Agouridakis P 625-628(CR) AIDS endobronchial non-Hodgkin's lymphoma in 697-699(CR) Pneumocystis carinii pneumonia, interleukin-8 and eucosanoid production in lung during 285-290 Ainslie GM 63-64 Air filtration units 394(L), 714-715(L) leak in pneumothorax, resolution time course 129-132 pollution, ozone toxicity and 647-656

Airflow limitation, chronic, influenza immunization status and viral respiratory tract infections in 559-561

obstruction in bronchial carcinoma, related to breathlessness and response to therapy 291–296

chronic, zardaverine effect on airway function 441-444

disease, inflammatory, mucus production 315-316 hyperresponsiveness in asthma, menthol vapour effect 503-504(SR)

hysteresis and lung parenchyma 317–322 responsiveness, asthma symptoms and bronchoconstriction recognition 181–185

Akosa A 73–75 Alfentanil sedation for bronchoscopy 53–56 Ali Türkmen M 581–582(CR) Allen MB 153(L),223–225(CR)

Allen MJ 101–104

Almoharab FI 701–703(CR)

Akkoçlu A 581-582(CR)

damage in neonatal sepsis, human neutrophil elastase distribution 505-507(CR)

haemorrhage, pulmonary metastases simulating 67-68 lavage fluid cytological, immunocytochemical and biochemical

lavage fluid cytological, immunocytochemical and biochem reference values 85–92

Alveolitis

cryptogenic fibrosing, in platypnoea-orthodeoxia 387–389(SR) in toxic gas leak victims 105–111
Ameen K 697–699(CR)

Amino acid N-terminal flanking peptide assay for hypercalcitonaemia in burns 41–46 Amiodarone pneumonitis 233–235(CR)

Anaesthesia blood pH evolution secondary to rise in alveolar tension of CO₂ during apnoea 393-394(L)

for nasal biopsy 161–169 Analgesia in fibre optic bronchoscopy 153(L) Andersen PB 175–179

Anderson M 113-120 Angio-oedema, hereditary, bronchoscopy in 305-306(CR) Animal model

for oxygen-induced lung injury 607-613 Ankylosing spondylitis, steroid therapy for pleural effusion 509-

Anorexia nervosa, cor pulmonale from untreated asthma and 631-633(CR)

Anti-Jo-1 syndrome 639-641(CR) Antibody detection for mycobacteria 403 Antigen detection for mycobacteria 400

511(CR)

Antimicrobial chemotherapy, aetiology of community-acquired pneumonia and 187-192

 al anti-trypsin deficiency, smoking and nicotine gum benefiting ulcerative colitis in 635–636(CR)

Arnold AG 377-379(SR) Arreiro JM 297

Arreiro JM 297 Arseniou P 307(CR)

Ashcroft T 387–389(SR)

Askin tumour 705-708(CR)

Askitopoulou E 625-628(CR) Aspergillosis

invasive, following bilateral lung transplant in cystic fibrosis 449-451(CR)

nasal biopsy 161-169

pulmonary and bronchopulmonary 143-145(CR)

Asthma

admission for adult Asians in Blackburn 1991–1992 415–417 bronchial, and granulocyte-macrophage colony stimulating factor 713(L)

713(L) budesonide dosing regimens comparisons 537–543 deaths, preventable factors and death certification 21–25

early, inflammation in 461-462(E)

fluticasone propionate preclinical and clinical experience 3-18(S) follow-up 547-554

inflammation monitoring by serum eosinophilic cationic protein levels 1-2(E)

knowledge and management by Ghanaian doctors 35–39 lung function changes with, dyspnoea perception in 477–485 management, at different ages 409–413

knowledge of patients with home nebulizers 487–493 and morbidity in Australian general practice 665–672 mortality, geographical and social class effects 341–346 occupational, due to chloramine-T solution 693–695(CR)

in older children, salmeterol effects 435-440 prevalence in French cities 685-692

symptoms, airway responsiveness and bronchoconstriction recognition 181–185

treatment, abrupt vs tailing off of corticosteroid therapy 101-104 changes, FEV₁ measurement 171-174

in childhood 153-155(L)

methology 363–368 menthol vapour effect on airway hyperresponsiveness 503– 504(SR)

untreated, cor pulmonale from 631-3(CR)

Attfield L 311–312(L)

Audit

in chest clinic consultation 583(L)

of pulmonary function laboratories in West Midlands 263-270 Autoimmune hypothyroidism with idiopathic pulmonary haemosiderosis, effect of cimetidine treatment 307-309(CR)

Avery AJ 181-185 Aw TC 711-712(L) Ayres JG 603-605

Azathioprine-induced polyarthritis for interstitial lung disease 63-64

Backer V 547-554 Backman R 85-92

Baez-Giangreco A 701-703(CR)

Baldwin DR 599-601

Balloul-Declaux E 237-238(L) Bar-Ziv Y 381-383(SR)

Bar-Ziv Y 381-383(SR)

Barbero EA 311(L)

Basal cell skin cancer, endobronchial metastasis 215-217(CR)

Bassiokas K 215–217(CR) Bateman ED 63–64 Bates AJ 599–601 Bauman A 665-672 Bronchoscopy Beach JR 181-185, 711-712(L) bedside fibreoptic, for tracheostomy decannulation 571-575(CR) Becker KL 41-46 CO2 laser 394-395(L) Benfield TL 285 fibreoptic, analgesia and sedation in 153(L) Benito N 297 in pulmonary tuberculosis 621-623 Berkman N 381-383(SR) sedation for 53-56 Berylliosis, nasal biopsy 161-169 in hereditary angio-oedema 305-306(CR) Bhandari S 155(L) Brusasco V 317-322 Bhasale A 665-672 Buccheri G 587-597 Blood pH evolution secondary to rise in alveolar tension of CO2 Bucillamine causing dry cough in eosinophilic bronchitis 219during apnoea in anaesthesia 393-394(L) 221(CR) Bloom A 381-383(SR) Budesonide **Book Reviews** dosing regimens comparisons 537-543 Assisted ventilation at home 445 effects on lung function and bronchial hyperresponsiveness in Bronchitis 709 cystic fibrosis 209-214 Clinical development of drugs against asthma 151 Buick JB 714 (L) Diseases of the bronchioles 152 Bullectomy, thoracoscopic, in spontaneous pneumothorax 563-Indoor allergens 391-392 566(SR) Lung surfactant: basic research in the pathogenesis of lung disorders Burns, pulmonary sequelae 41-46 Bye A 3-18(S) Occupational lung disorders (3rd edn) 456 Pharmacology and therapeutics in respiratory care 455-456 Calderon MA 161-169 Pneumocystis carinii pneumonia 151 Caldwell NA 57-59(SR) The Badger 643-644 Callol L 393-394(L) Therapeutics in respiratory disease 391 Calori G 337-340 Campbell M 711-712(L) Boshnakova T 147-149(CR) Bourke S 193-198 Campodarve I 67-68 Bourke SJ 387-389(SR) Canda T 581-582(CR) Bouros D 307(CR),625-628(CR) Candida tropicalis causing pulmonary mycetoma-like lesion 303-Bousquet J 329-335,685-692 4304(CR) Bradbury SP 599-601 Carbon dioxide Bradford B 311-312(L) alveolar tension rise in anaesthesia, blood pH rise secondary to 393-394(L) Brain natriuretic peptide levels in pulmonary arterial hypertension laser bronchoscopy 394-395(L) 445-447(CR) Carcinoembryonic membrane marker for lung cancer 587-597 Breathing pattern, nocturnal, in COPD 615-616 Carcinoid tumours, atypical bronchial 133-138(CR) Breathlessness and airflow obstruction in bronchial carcinoma 291-Carina carcinoma, pneumomediastinum in 385-386(SR) 296 Carlen R 153(L) Bredin CP 69-71 Cartier A 537-543 Brettle RP 495-497 Casas FJ 393-394(L) Bridges-Webb C 665-672 Castronovo V 337-340 Bright P 603-605 Catheterisation, superior vena cava obstruction 396-397(L) Britton JR 341-346 Cayton RM 603-605 Brochwicz-Lewinski MJ 113-120 Cazzadori A 143-145(CR) Bronchial biopsies, Fos immunoreactivity assessment 329-335 Cazzola M 357-362 Bronchial carcinoid tumours, atypical 133-138(CR) Cevik N 581-582(CR) Bronchial carcinoma, airflow obstruction related to breathlessness Chaiprasert A 621-623 and response to therapy 291-296 Chakraverty P 559-561 Bronchial exposure to NO2 effect on smooth muscle response Chamberlain MJ 15-19 323-328 Chan SL 3-8 Bronchial hyperreactivity Chan WM 639-641(CR) in cystic fibrosis, effects of budesonide 209-214 Chanarin N 409-413 in endobronchial tuberculosis 419-422 Chanez P 329-335 respiratory symptoms and 93-100 Charoenratanakul S 621-623 Chemotherapy of tuberculosis 463-469 Bronchial responsiveness to histamine and methacholine 351-356 Bronchiectasis complicating rheumatoid arthritis 453-454(CR) Chest clinic audit 583(L) Chest wall neuroectodermal tumour 705-708 Bronchitis, eosinophilic, presenting with dry cough from bucillamine Chiba H 509-511(CR) 219-221(CR) Chidley K 637-638(CR) Bronchoalveolar lavage Chillon MJ 77(L) analysis from lung transplant recipients by flow cytometry 27-34 Chitano P 323-328 findings after cimetidine therapy for idiopathic pulmonary haemosiderosis with autoimmune hypothyroidism 307-Chiyptani A 503-504(SR) 309(CR) Chlamydia psittacci infection, neurological complications 637-Bronchoarterial pulmonary malinosculation in child 147-149(CR) 638(CR) Bronchoconstriction Chloramine-T solution causing occupational asthma 693-695 following inhaled ethanol solutions 457-458(L) Choy A-M 445-447(CR) methacholine-induced, effect of nasal CPAP on 121-128 Chromogranin A marker for lung cancer 587-597 recognition 181-185 Chronic obstructive pulmonary disease (COPD) Bronchodilator therapy effects on airflow obstruction in bronchial effect of salmeterol and formoterol 357-362 carcinoma 291-296 long-term oxygen therapy improvement of skeletal muscle Bronchofibrescopes, eradication of Mycobacterium chelonae 423metabolism and 471-476

Bronchopulmonary aspergillosis, allergic 143-145(CR)

lung function changes with, dyspnoea perception in 477-485

nocturnal oxygen and exercise-induced desaturation in 599-601

saturation and breathing pattern in 615-616 Ciaccia A 323-328 Cimetidine therapy effects on idiopathic pulmonary haemosiderosis with autoimmune hypothyroidism 307-309(CR) Clarke JR 373-376(SR) Clayberger C 27-34 Coca S 77(L) Cohen P 381-383(SR) Coker RJ 373-376(SR) Collazos J 463-469 Collins JV 305(CR) Collol L 77(L) Congleton J 291 Constantopoulos SH 215-17(CR) Continuous positive airway pressure effect on methacholine-induced bronchoconstriction 121-128 home nebulizer provision 47-52 in obstructive sleep apnoea, use of Epworth Sleepiness Scale 617-620 oxygen desaturation during sleep and exercise 193-198 QTc interval, autonomic neuropathy and mortality 79-84 reversal of orthodeoxia and platypnoea in organophosphorus poisoning 625-628(CR) salbutamol treatment regimens compared 175-179 Turbuhaler or nebulizer therapy 77-78(L) Conway SP 396-397(L) Cooke NJ 101-104 Cooper C 665-672 Cooper SM 53-56 Cöplü L 237(L) Cor pulmonale from untreated asthma and anorexia nervosa 631-633(CR) Corne J 409-413 Corominas JM 67-68

Coronary angioplasty, spontaneous haemothorax complicating anti-coagulation 629-630(CR) Corris PA 387-389(SR) Corticosteroid withdrawal in asthma, abrupt vs tailing off 101-104 Cortisol excretion in urine following inhaled glucocorticosteroids 347-349

Coser E 323-328 Couderc LJ 237-238(L) Cowie J 637-638(CR) Craig SR 385-386(SR)

Creatine-phosphokinase-BB marker for lung cancer 587-597 Crimi N 227-231(CR)

Cryptogenic fibrosing alveolitis, platypnoea-orthodeoxia in 387-389(SR)

Cryptogenic organizing pneumonitis 271-278 anti-Jo-1 syndrome presenting as 639-641(CR) Cullen J 129-132

Curtin J 69-71 Curull V 67-68

CYFRA 21-1 marker for lung cancer 587-597

Cystic fibrosis

effects of budesonide on lung function and bronchial hyperresponsiveness 209-214

GI loss 577-579(CR)

invasive aspergillosis after bilateral lung transplant 449-451(CR) rhDNase for pulmonary disease in 499-502

superior vena cava obstruction 396-397(L) Cytomegalovirus infection in lung transplant recipients, bronchoalveolar lavage analysis by flow cytometry 27-34

D'Amato G 357-362 Dahl R 525-527(E) Dar KJ 545-546 Davies D 1(S) Davies L 559-561 Davies RJ 161-169 Davies S 101-104

De Jongh BM 449-451(CR) de Maertelaer V 477-485

Death certification in asthma deaths 21-25 Deep vein thrombosis diagnosis 241-251

Dejsomritrutali W 621-623

Della Marca G 337-340 Demir AU 237(L)

Demoly P 329-335 Dent R 311-312(L)

Denyer J 157-159(E) Deviri E 381-383(SR)

Ditcher JR 285

Dihenker J 153(L) Dirksen A 547-554

DNase I, human recombinant, for pulmonary disease in cystic fibrosis 499-502

Drebov R 147-149(CR) Drent M 449-451(CR)

Drying chamber for nebulisers 567-569(SR)

Duiic Z 9-14

Dykhuizen RS 61-62(CR)

Dyspnoea perception in lung function changes in asthma of COPD 477-485

Earis J 559-561

ECG QTc interval, autonomic neuropathy and mortality in COPD

Echocardiography for pulmonary embolism diagnosis 241-251

Edwards AM 153-155(L)

Eicosanoid production in lung during pneumonia in AIDS 285-290 El-Solh A 697-699 (CR)

Elshout FJJ vp 351-356

Emphysematous bulla spontaneous closure 377-379(SR)

Empyema, lung carcinoma causing 73-75

Endobronchial leiomyoma mimicking asthma 581-582(CR)

Endobronchial metastasis from basal cell skin cancer 215-217(CR) Endobronchial non-Hodgkin's lymphoma in AIDS 697-699(CR)

Eosinophil cationic protein levels in asthma inflammation monitoring 1-2(E)

Eosinophilia, pulmonary, from minocycline 61-62(CR)

Epworth Sleepiness Scale use in nasal continuous positive airways pressure in obstructive sleep apnoea 617-620

Erythromycin therapy for sinobronchial syndrome, ofloxacin addition therapy effect 677-684

Escort spirometer 657-663

Eterovic D 9-14

Ethanol inhalation, bronchoconstriction following 457-458(L)

Ethnic discounting and spirometry 312-313(L)

Evans AH 599-601

Evans CC 631-633(CR)

Everard ML 567-569(SR)

Exercise, oxygen desaturation in COPD 193-198,599-601

Fabbri LM 323-328

Feldman C 187-192

Fennerty AG 53-56

Ferini-Strambi L 337-340

Ferrer JE 303(CR)

Ferrigino D 587-597

Festen J 209-214

FEV₁ measurement for asthma treatment changes 171-174

Fibronectin levels in toxic gas leak victims 105-111

Filcek SAL 153-155(L)

Fine needle aspiration for diagnosis of lung cancer metastases 545-546

Finkle C 27-34

Fitzpatrick M 193-198

Flank pain in pulmonary embolism 65-66

Flow cytometry analysis of bronchoalveolar lavage from lung transplant recipients 27-34

Flumazenil for midazolam sedation reversal 78(L)

Fluticasone propionate preclinical and clinical experience 3-18(S) vs sodium cromoglycate for childhood asthma 363-368 Folgering H 93-100,351-356 Folgering HThM 615-616 Foreign body aspiration causing delayed acute necrotizing pneumonia 139-141(CR) Foresti V 238-239(L) Formoterol effect in COPD 357-362 Fos immunoreactivity assessment on bronchial biopsies 329-335 Fountain SW 563-566(SR) Fox R 559-561 Franck N 237-238(L) Free radical initiation by ozone 647-656 French D 435-440 French N 559-561 Fröseth B 85-92 Fujimura M 219-221(CR),677-684 Fuiita J 505-507(CR) Fuller R 3-18(S) Fuller RW 525-527(E) Functional tests see lung function tests Fungal infection, nasal biopsy 161-169 Gallbladder wall thickening as sign of pulmonary embolism 238-239(L) Gallus G 337-340 Ganassini A 143-145(CR) Ganderton D (ed) 253 Gas exchange in pleural effusion patients, effect of body position 297-301 leak, toxic, causing lung inflammation 105-111 Gastrointestinal blood loss in cystic fibrosis 577-579(CR) Gauthier-Rouvière C 329-335 Geddes DM 499-502 Ghezzo H 537-543 Gibson GJ 387-389(SR),529-535 Gil J 297 Girling DJ 394-395(L) Gittins DP 457-458(L) Glucocorticosteroids, systemic effects in children 347-349 Gooch R 263 Godard P 329-335 Gomez-Terreros FJ 77(L),393-394(L) Goolam Mahomed A 187-192 Grange JM 313-314(L) Grant IWB 583(L) Granulocyte colony-stimulating factor for small cell lung cancer,

necrotizing vasculitis and psoriasis exacerbation following 237-238(L)

Greenough A 429-433 Greenstone MA 47-52 Gregson RK 487-493 Greig JH 53-56 Groot CAR 209-214 Guasch M 393-394(L)

Guinea pig bronchi exposure to NO2 effect on smooth muscle response 323-328

Haahtela T 461-462(E)

Haemosiderosis, pulmonary idiopathic, with autoimmune hypothyroidism, effect of cimetidine treatment 307-309(CR) Haemothorax, spontaneous, complicating anti-coagulation follow-

ing coronary angioplasty 629-630(CR) Hallett C 525-527(E)

Hancox M 712(L) Hansen NCG 77-78(L),175-179 Hardinge FM 78(L),617-620 Haren EHJ van 209-214 Harris JRW 373-376(SR) Hatton MQF 101-104 Hayton R 263

Hegarty JM 279 Heijerman HGM 209-214 Heikkinen K 693-695 Heki U 219-221(CR) Hendrick DJ 181-185 Henry C 685-692 Henselmans JML 139-141(CR)

Heparin therapy following coronary angioplasty, spontaneous haemothorax complicating 629-630(CR)

Hernández L 297 Herwaarden CAL van 209-214,351-356 Hesse IFA 35-39 Higgins BG 341-346

Hirasawa M 509-511(CR) Histamine, bronchial responsiveness 351-356 Histoplasmosis, nasal biopsy 161-169

pulmonary, in Pneumocystic carinii pneumonia 373-376(SR) Mycobacterium tuberculosis and 495-497 Hobbs J 435-440 Hodson ME 499-502 Hogan J 69-71 Holgate ST 409-413,647-656 Hoogen HJM van den 93-100

Hooper G 457-458(L) Horsfield N 555-557 Hosker HSR 3-8,47-52,458(L)

House dust mite allergen, vacuum cleaner effects 279-284 Howard P 79-84

Huang Tung-Jung 121-128 Hughes P 637-638(CR) Humpherson C 311-312(L) Hypercalcitonaemia in burns patients 41-46

Hyperoxic lung in rat, N-acetylcysteine effects 311(L)

Hypoxaemia in COPD, long-term oxygen therapy improvement of skeletal metabolism and 471-476

Imamuma T 453-454(CR) Inflammation in early asthma 461-462(E) Influenza immunization status in chronic airflow limitation 559-561 Inhaled drugs, equivalences 253-261,525-527(E)

Interleukin-2 receptor marker for lung cancer 587-597 Interleukin-8 production in lung during pneumonia in AIDS 285-

290 Ip M 639-641(CR) Ishura Y 677-684 Itoh E 509-511(CR)

Jakobsson P 471-476 Janssen JLM 93-100 Jeng J 41-46 Jenkins G 73-75 Jennings B 537-543 Jensen BN 285 Jeong SW 419-422 Jewitt DE 629-630(CR) Johnson AOC 223-225(CR)

Johnson M 3-18(S) Johnston IDA 129-132 Jones KP 171-174,657-663 Jordan MH 41-46

Jorfeldt L 471-476 Junge J 285 Junod AF 241

Kiely JL 69-71

Kallis P 563-566(SR) Karakoca Y 237(L) Kasimbazi HJN 53-56 Kavente ML 395-396(L) Keaney NP 577-579(CR) Kelly FJ 607-13,647-656 Kendrick AH 157-159(E) Kikuchi's disease presenting as bilateral hilar lymphadenopathy tests in asthma follow-up 547-554 in neonates 429-433 701-703(CR) Kim HT 419-422 Lung inflammation in toxic gas leak victims 105-111 Kim KU 419-422 Lung parenchyma, airway hysteresis and 317-322 Kim YH 419-422 Lung tissue, non-neoplastic, NK cells 77(L) King ME 15-19 Lung transfer factor increase in sarcoidosis 9-14 Kinnear WJM 129-132 Lung transplant Kisacik G 237(L) invasive aspergillosis in cystic fibrosis following 449-451(CR) Kitagawa M 219-221(CR) recipient bronchoalveolar lavage analysis by flow cytometry 27-34 Klebsiella pneumoniae isolated in community-acquired pneumonia Lymphadenopathy, bilateral hilar, Kikuchi's disease presenting as 187-192 701-703(CR) Knani J 685-692 Lymphangioleiomyomatosis, pneumothorax in 381-383(SR) Koch C 547-554 Lymphocyte subset analysis in bronchoalveolar lavage from lung Kodaira S 453-454(CR) transplant recipents by flow cytometry 27-34 Kolnaar BGM 93-100 Lymphoma, endobronchial non-Hodgkin's, in AIDS 697-699 Konno K 503-504(SR) Kox LFF 399-408 Ma HK 3-8 McAlpine HM 445-447(CR) Kramer MR 381-383(SR) Krishna MT 647-656 MacDonald TM 445-447(CR) Kubo K 271 McIntyre P 311-312(L) Kujala VM 693-695 McNicholas WT 193-198 Maestrelli P 323-328 Kuo Han-Pin 121-128 Magnano M 227-231(CR) Laing R 495-497 Malo J-I, 537-543 Lam CW 3-8 Maniati MA 215-217(CR) Lammers J-WJ 209-214 Manresa F 303(CR) Lang CC 445-447(CR) Mapp CE 323-328 Langton Hewer S 435-440 Marrero R 393-394(L) Lant AF 305(CR) Martin C 297 Lau CS 639-641(CR) Martin-Larrauri R 393-394(L) Lavelle RJ 161-169 Martinez E 463-469 Lee SM 419-422 Matera MG 357-362 Lee T-S 571-575(CR) Mathur R 129-132 Matsuda T 219-221(CR),677-684 Leen CLS 495-497 Legge JS 61-62(CR) Mayo J 463-469 Meacher RL 305(CR) Leiomyoma, endobronchial, mimicking asthma 581-582(CR) Leitch AG 113-120,369-371(SR),495-497,583(L) Meningo-encephalitis in psittacosis 637-638(CR) Lenney W 435-440 Menthol vapour effect on airway hyperresponsiveness in asthma 503-504(SR) Leprosy, nasal biopsy 161-169 Lessana-Liebowitch M 237-238(L) Metered-dose inhalers 253-261 Leukocytes, peripheral blood, analysis in bronchoalveolar lavage Methacholine from lung transplant recipients by flow cytometry 27-34 bronchial responsiveness 351-356 McAlpine HM 445-447(CR) Leukotriene B₄ role in oxygen-induced lung injury 607-613 Lewis MS 41-46 methacholine-induced bronchoconstriction, effect of nasal CPAP Lewis RA 635-636(CR) 121-128 Michailova V 147-149(CR) Liard R 685-692 Lin Horng-Chyuan 121-128 Michel F-B 329-335 Lipschik GY 285 Midazolam sedation Lowry RC 714 (L) for bronchoscopy 53-56 Lucas MC 311(L) reversal with flumazenil 78(L) Lucchini RE 323-328 Miles D 665-672 Ludeña MD 311(L) Miles JF 603-605 Miliary tuberculosis in Blackburn 1978-1993 555-557 Lundgren JD 285,315-316(E) Miller JA 705-708(CR) Miller MR 603-605 differences in particle disposition 15-19 fibre particles and 717 Milner AD 567-569(SR) Milrov R 57-59(SR) Lung cancer Mini-Wright peak flow meter 657-663 causing empyema 73-75 Minocycline-induced pulmonary eosinophilia 61-62(CR) metastases diagnosis by fine needle aspiration 545-546 Misra NP 105-111 serum markers 587-597 small cell, necrotizing vasculitis and psoriasis exacerbation after G-CSF for 237-238(L) Mistretta A 227-231(CR) Mitchell DM 373-376(SR) rectal metastasis 223-225(CR) Miyawaki H 505-507(CR) Lung disease, interstitial Model D 21-25 Moghissi K 394-395(L) azathioprine-induced 63-64 Mohammed W 607-613 fibrogenic mechanisms 518(A) Monie RDH 53-56 Lung function changes in asthma or COPD, dyspnoea perceptino in 477-485 Moreno-Muro F 77(L) Morgan WKC 15-19 in cystic fibrosis, effects of budesonide 209-214 measurement for asthma treatment changes 171-174 Morris J 537-543 Mucus production in inflammatory airway diseases 315-316(E) in general practice 657-663 Mudway I 647-656 studies of bronchial responsiveness to histamine and methacholine 351-356 Muers MF 47-52.291

Mullee MA 657-663 Mulloy E 193-198 Munro NC 387-389(SR) Muscle metabolism, skeletal, oxygen therapy and 471-476 Mushitag M 263 Mutton K 559-561 Mycobacteria detection and identification tests 399-408 non-tuberculous 458(L) causing pulmonary infection 3-8 tenosynovitis from 69-71 Mycobacterium chelonae eradication from bronchofibrescopes 423-427 Mycobacterium kansasii causing tenosynovitis 69-71 Mycobacterium marinum causing tenosynovitis 69-71 Mycobacterium tuberculosis infection in HIV-positive patients in Edinburgh 495-497 Mycobacterium vaccae immunotherapy for pulmonary TB 199-207 Nakatsumi Y 677-684 Nasal biopsy 161-169 Nasal CPSP effect on methacholine-induced bronchoconstriction 121-128 Nebulization practice optimization in hospital 57-59(SR),711-712(L) Nebulizer comparisons in COPD treatment 175-179 for COPD, provision at home 47-52 drying chamber for 567-569(SR) fill volume, residual volume and matching to compressor 157-159(E) home, asthma management knowledge of 487-493 service at home 311-312(L) vs Turbuhaler in severe COPD 77-78(L) Necrotizing vasculitis and psoriasis exacerbation after G-CSF for small cell lung carcinoma 237-238(L) Neonatal sepsis, human neutrophil elastase distribution 505-507(CR) Neukirch F 685-692 Neural cell adhesion molecule marker for lung cancer 587-597 Neuroectodermal tumour of chest wall 705-708 Neurological complications in psittacosis 637-638(CR) Neuron-specific enolase marker for lung cancer 587-597 Neuropathy in hypoxaemic COPD 79-84 Neutrophil elastase, human, distribution in alveolar damage and pneumonia in neonatal sepsis 505-507(CR) Newman SP 457-458(L) Ng TK 3-8 Nicotine gum benefiting ulcerative colitis in al anti-trypsin deficiency 635-636(CR) Nielsen TL 285 Nitrogen dioxide exposure effect on bronchial smooth muscle response 343-348 Niven RMCL 714-715(L) NK cells in non-neoplastic lung tissue 77(L) Nomura M 677-684 Noseda A 477-485 Nucleic acid amplification for mycobacteria 401-402 Nylen ES 41-46 O'Driscoll R 77-78(L) O'Neill WJ 41-46 O'Regan A 193-198

Omar J 187-192 Onyebujoh PC 199-207 Organophosphorus poisoning, orthodeoxia and platypnoea reversal by CPAP 625-628(CR) Ormerod LP 415-417,555-557 Orthodeoxia in organophosphorus poisoning reversal by CPAP 625-628(CR) Oto Ö 581-582(CR) Outpatient information, patient satisfaction with 673-676 Oxygen desaturation during sleep and exercise in COPD 193-198,599--induced lung injury, role of leukotriene B₄ in 607-613 therapy, long-term, skeletal muscle metabolism in COPD and 471-476 Özaksoy D 581-582(CR) Ozone toxicity 647-656 P388D1 cells 522(A) Paediatric asthma treatment 153-155(L) Pain, flank, in pulmonary embolism 65-66 Panagou P 307(CR) Pantin CFA 599-601 Papagiannis A 673-676 Papi A 323-328 Papiris SA 215-217(CR) Parameswaran K 577-579(CR) Park CS 419-422 Patterson G 27-34 Peak flow meters, Mini Wright, performance after long-term use 603-605 Pedersen M 547-554 Pedersen S 347-349 Peh WCG 639-641(CR) Pellegrino R 317-322 Perks WH 263 Perrier A 241 Philippe B 237-238(L) Phillips GJ 607-613 Phycomycoses, nasal biopsy 161-169 Pickering CAC 714-715(L) Pillans PI 63-64 Pin I 685-692 Pison C 685-692 Pitson DJ 617-620 Pitvn P 15-19 Plasma D-dimer 241-251 Platypnoea in organophosphorus poisoning reversal by CPAP 625-628(CR) -orthodeoxia in cryptogenic fibrosing alveolitis 387-389(SR) Pleural effusion in ankylosing spondylitis, steroid therapy 509-511(CR) hepatocyte growth factors/scatter factor in cancer 522(A) patients, effect of body position on gas exchange 297-301 Pleurodesis, tetracycline, in spontaneous pneumothorax 563-566(SR) Pneumomediastinum in carina carcinoma 385-386(SR) Pneumonia acute necrotizing, 16 years after conifer branch aspiration 139-141(CR)

aetiology of community-acquired, impact on antimicrobial

in neonatal sepsis, human neutrophil elastase distribution 505-

chemotherapy 187-192

507(CR)

Pneumocystic carinii, pulmonary HIV infection 373-6(SR) pneumonitis

amiodarone 233-235(CR) cryptogenic organizing 271-278

Pneumothorax

in lymphangioleiomyomatosis 381-338(SR) resolution time course of air leak 129-132

spontaneous, thoracoscopic bullectomy and tetracycline pleurodesis in 563-566(SR)

Polkey MI 233-235(CR) Pollock M 665-672 Polosa R 227-231(CR)

Polyarthritis induced by azathioprine for interstitial lung disease

Postmus PE 139-141(CR) Prasad N 445-447(CR) Prats E 303(CR) Price JF 363-368

Prigogine T 477-485 Prior AJ 161-169 Protozoan infection, nasal biopsy 161-169

Psittacosis 155(L) neurological complications 637-638(CR)

Psoriasis exacerbation after G-CSF for small cell lung carcinoma 237-238(L)

Pujol J-L 329-335 Pulmonary angiography 241-251

Pulmonary artery hypertension, brain natriuretic peptide levels 445-447(CR)

Pulmonary aspergillosis, invasive 143-145(CR)

Pulmonary disease

chronic obstructive see under chronic in cystic fibrosis, rhDNase for 499-502

Pulmonary embolism diagnosis 241-251 flank pain 65-66

gallbladder wall thickening as sign of 238-239(L) Pulmonary eosinophilia from minocycline 61-62(CR)

Pulmonary function

laboratories audit in West Midlands 263-270

see also lung function

Pulmonary haemosiderosis, idiopathic, with autoimmune hypothyroidism, effect of cimetidine treatment 307-309(CR) idiopathic 714(L)

Pulmonary HIV infection in Pneumocystis carinii pneumonia 373-376(SR)

Pulmonary infection from non-tuberculous mycobacteria 3-8 Pulmonary infiltrates in sarcoidosis 237(L)

Pulmonary metastases from renal caell carcinoma simulating alveolar haemorrhage 67-68

Pulmonary mycetoma-like lesion from Candida tropicalis 303-304(CR)

Pulmonary sequelae following burns 41-46 Pulmonary sequestration in child 147-149(CR)

Pulmonary tuberculosis

Mycobacterium vaccae immunotherapy 199-207 use of fibreoptic bronchoscopy 621-623

Pulmonary tuberous sclerosis 227-231(CR)

Radford M 487-493 Ramael MRL 133-138(CR)

Rectal metastasis from small cell lung cancer 223-225(CR)

Rees PJ 233-235(CR) Reiber C 441-444 Reid A 559-561

Reijula KE 693-695(CR)

Renal cell carcinoma pulmonary metastases simulating alveolar haemorrhage 67-68

Rentz K 441-444

Respiratory muscle strengths 529-535

Respiratory symptoms and bronchial hyperresponsiveness 93-100 Respiratory tract infectiions in chronic airflow limitation 559-561 Reynolds S 73-75

Rheumatoid arthritis, bronchiectasis complicating 453-454(CR)

Rhinoscleroma, nasal biopsy 161-169

Rhinosporidiosis, nasal biopsy 161-169 Richards A 457-458(L)

Richards R 673-676 Riley M 714(L)

Riska H 85-92

Roberts CM 73-75

Robinson NMK 629-630(CR)

Robinson S 199-207

Rogers DF (ed) 253

Romazzini S 685-692

Romberger C 705-708

Romero S 297

Rook GAW 199-207

Ross S 187-192

Rossi F 357-362

Roubbakhsh S 279

Rubilar M 113-120,495-497

Rubin I 457-458(L)

Ruotsalainen E-M 693-695(CR)

Sabri Uçan E 581-582(CR)

Saetta M 323-328

Saito M 677-684 Sakai A 503-504(SR)

Salbutamol treatment regimens compared in COPD 175-179

Salmeterol effect

in asthma in older children 435-440

in COPD 357-362

Sánchez-Gascón F 311(L) Sanjuás C 67-68

Sankaran K 105-111

Sans J 303(CR)

Santangelo G 357-362 Sarcoidosis

lung transfer factor increase in 9-14

pulmonary infiltrates 237(L)

Scadding JG 458(L)

Schmerber J 477-485

Schramel FMNH 139-141(CR)

Scott

SF 499-502

Sedation

for bronchoscopy 53-56,153(L)

reversal with flumazenil 78(L)

Selby C 369-371(SR)

Serum markers for lung cancer 587-597

Shah PL 499-502

Shale DJ 673-676

Sharma SK 105-111

Sheehan S 69-71

Shelhamer JH 285

Sherif S 697-699(CR)

Shibata K 677-684

Shibusa T 509-511(CR)

Shieh Wen-Bin 121-128 Shikata Y 271

Shimon D 381-383(SR)

Shurvinton J 263

Siafakas NM 307(CR),625-628(CR)

Sinobronchial syndrome, ofloxacin additive therapy effect on erythromycin therapy for 677-684

Sivanathan UM 396-397(L)

Skeletal muscle metabolism, oxygen therapy and 471-476

Skin

cancer, basal cell, endobronchial metastasis 215-217(CR)

tests for mycobacteria 403-404

Tuberculosis Sleep apnoea, obstructive, use of Epworth Sleepiness Scale in continucattle: 'VL, open' cases . . . or 'NVL, non-infectious' cases 712(L) ous positive airways pressure 617-620 chemotherapy 463-469 oxygen desaturation in COPD 193-198 contact procedures in Edinburgh 1982-1991 113-120 endobronchial, bronchial hyperreactivity 419-422 Small cell lung cancer miliary, in Blackburn 1978-1993 555-557 necrotizing vasculitis and psoriasis exacerbation following G-SCF for 237-238(L) mortality in Edinburgh 1983-1992 369-371(SR) rectal metastasis 223-225(CR) nasal biopsy 161-169 Smirne S 337-340 pulmonary, Mycobacterium vaccae immunotherapy 199-207 Smith C 187-192 use of fibreoptic bronchoscopy 621-623 Smith DL 350(CR) time-table 313-314(L) Smith EC 157-159(E) Tuberculostearic acid tests 400 Tuberculous empyema presenting after oleothorax 153(L) Smoking Tuberous sclerosis, pulmonary 227-231(CR) benefiting ulcerative colitis in 1 anti-trypsin deficiency 635-Tumours, nasal biopsy 161-169 636(CR) on health premises 395-396(L), 715(L) Turbine spirometer 657-663 Smooth muscle response in guinea pig bronchus following NO2 Turbuhaler or nebulizer therapy in severe COPD 77-78(L) exposure 323-328 Turton C 715(L) Snider RH 41-46 Twins, snoring 337-340 Snoring in twins 337-340 Uh S 419-422 Sodium cromoglycate vs fluticasone propionate for childhood Ukena D 441-444 asthma 363-368 Spirometer vs peak flow meter for lung function measurement Ulcerative colitis responsive to smoking and nicotine gum in '1 anti-trypsin deficiency 635-636(CR) 657-663 Spirometry and ethnic discounting 312-313(L) Ulrik CS 547-554 Squamous cell carcinoma Urine cortisol excretion and knemometry in children following inhaled glucocorticosteroids 347-349 antigen marker for lung cancer 587-597 Stanford JL 199-207 Starnes VA 27-34 Vacuum cleaners effects on house dust mite allergen 279-284 Steed KP 457-458 Valldeperas J 303(CR) van den Bosch JMM 449-451(CR) Stenton SC 181-185,711-712(L) Steroid therapy, intra-pleural, for pleural effusion in ankylosing van Herwaarden CLA 615-616 spondylitis 509-511(CR) Van Marck EAE 133-138(CR) Stewart AG 79-84 Van Meerbeeck JPA 133-138(CR) Stoehr C 27-34 van Rens MThM 449-451(CR) Van Schil PEY 133-138(CR) Stradling JR 617-620 Streptococcus pneumoniae isolated in community-acquired pneuvan Steenwuk R 285 monia 187-192 van Velzen-Blad H 449-451(CR) Struthers AD 445-447(CR) Vanchieri C 227-231(CR) Struyf NJA 133-138(CR) Vathenen AS 101-104 Veale D 577-579(CR) Superior vena cava obstruction in cystic fibrosis and catheterisation Velogianni EI 215-217(CR) 396-397(L) Supervia A 67-68 Venge P 1-2(E) Sutedja G 139-141(CR) Vermeire PA 133-138(CR) Sutinen S 85-92 Vestro J 316-317(E) Sutinen SH 85-92 Vijayan VK 105-111 Sybrecht GW 441-444 Villegas F 77(L) Syphilis, nasal biopsy 161-169 Vinciguerra A 357-362 Viral respiratory tract infections in chronic airflow limitation 559-Takahara J 505-507(CR) 561 Takanami I 453-454(CR) Vos PJE 615-616 Takenura H 503-504(SR) Takigawa K 505-507(CR) Wagenaar SjSc 449-451(CR) Tamaoki J 503-504(SR) Wahbi ZK 377-379(SR) Tanaka H 509-511(CR) Walker WS 385-386(SR) Teale C 47-52 Wang Chun-Hua 121-128 Tenosynovitis from non-tuberculous mycobacteria 69-71 Wang E 639-641(CR) Tetracycline pleurodesis in spontaneous pneumothorax 563-566(SR) Warburton CJ 714-715(L) Theodore J 27-34 Warner JA 279,394(L) Thomas MR 629-630(CR) Warner JO 279.394(L).487-493 Thompson KA 41-46 Water sports, tenosynovitis from non-tuberculous mycobacteria in Thomson D 369-371(SR) 69-71 Tissue polypeptide antigen marker for lung cancer 587-597 Waterhouse JC 79-84 Tocilj J 9-14 Waterworth PD 563-566(SR) Tomkovich K 705-708 Watson B 53-56 Tony JC 713(L) Watson JP 635-636(CR) Watt R 495-497 Tooke AFR 63-64 Townsend ER 563-566(SR) Watts T 263 Tracheostomy decannulation, bedside fibreoptic bronchoscopy for Weel C van 93-100 571-575(CR) Weersink EJM 351-356

Trudeau C 537-543

Tse M 665-672

Tsatsakis A 625-628(CR)

Weller PH 363–368 White JES 387–389(SR) White NW 312–313(L) Whitehead BF 27–34 Willcocks L 495–497 Williams TJ 78(L),545–546 Wilson GE 631–633(CR) Wilson POG 233–235(CR) Wolthers OD 347–349 Wu Y 571–575(CR)

Yamadori I 505-507(CR) Yamaji Y 505-507(CR) Yamamoto T 453–454(CR) Yamamoto Y 453–454(CR) Yang Cheng-Ta 121–128 Yates ND 313–314(L) Yeast infection, nasal biopsy 161–169 Yernault J-C 477–485 Yoshinouchi T 271 Yu Chih-Teng 121–128 Yüksel B 429–433

Zardaverine effect on airway function in chronic airflow obstruction 441–444
Zucconi M 337–340